Adjuvant Chemotherapy of Completely Resected Early Stage Non-small Cell Lung Cancer (NSCLC)

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806259

Citations 36

Authors

Ying Liang

Heather A Wakelee

Affiliations

Soon will be listed here.

Abstract

Surgery is regarded as the primary treatment modality for early stage non-small cell lung cancer (NSCLC), but even after complete resection, a substantial percentage of these patients eventually develop local recurrence or distant metastases. Therefore more effective treatment strategies to reduce lung cancer mortality and recurrence rate are needed. Only recently has the use of adjuvant chemotherapy become standard in early stage NSCLC, at least for stage II and resected IIIA NSCLC. Controversies remain about the benefit for stage I patients. Five-year survival improvements of 5% to 10% have been reported with cisplatin-based adjuvant chemotherapy from multiple large randomized phase III clinical trials and meta-analyses. Questions remain as to which patients benefit and which regimens are best. In this paper, important clinical research in the field of adjuvant chemotherapy of NSCLC is reviewed.

Citing Articles

Surgery versus concurrent chemoradiotherapy for stage III non-small cell lung cancer: a retrospective study with propensity score matching.

Shigenobu T, Taniguchi Y, Suzuki T, Tabuchi Y, Sato M, Odagiri K BMC Cancer. 2025; 25(1):121.

PMID: 39844071 PMC: 11753074. DOI: 10.1186/s12885-025-13550-0.

[Neoadjuvant therapy for resectable non-small cell lung cancer].

Welcker K, Jonigk D, Kropf-Sanchen C, Tufman A, Draube A, Stenzinger A Pneumologie. 2024; 79(1):16-24.

PMID: 39642922 PMC: 11753866. DOI: 10.1055/a-2465-4830.

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial).

Duan H, Shao C, Luo Z, Wang T, Tong L, Liu H Signal Transduct Target Ther. 2024; 9(1):296.

PMID: 39465257 PMC: 11514280. DOI: 10.1038/s41392-024-01992-0.

Pemetrexed and platinum with or without pembrolizumab for advanced non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis.

Zhao Z, Yang C, Li J Clin Transl Oncol. 2024; .

PMID: 39402420 DOI: 10.1007/s12094-024-03751-7.

Deep learning to estimate response of concurrent chemoradiotherapy in non-small-cell lung carcinoma.

Peng J, Zhang X, Hu Y, He T, Huang J, Zhao M J Transl Med. 2024; 22(1):896.

PMID: 39367461 PMC: 11451157. DOI: 10.1186/s12967-024-05708-4.

References

Butts C, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D . Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2009; 28(1):29-34. PMC: 2799232. DOI: 10.1200/JCO.2009.24.0333. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Scagliotti G, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C . Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3543-51. DOI: 10.1200/JCO.2007.15.0375. View

Bezjak A, Lee C, Ding K, Brundage M, Winton T, Graham B . Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008; 26(31):5052-9. PMC: 2652099. DOI: 10.1200/JCO.2007.12.6094. View

Waller D, Peake M, Stephens R, Gower N, Milroy R, Parmar M . Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004; 26(1):173-82. DOI: 10.1016/j.ejcts.2004.03.041. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Kreuter M, Vansteenkiste J, Fischer J, Eberhardt W, Zabeck H, Kollmeier J . Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2012; 24(4):986-92. DOI: 10.1093/annonc/mds578. View

Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T . Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77. PMC: 2853682. DOI: 10.1016/S0140-6736(10)60059-1. View

Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350(17):1713-21. DOI: 10.1056/NEJMoa032792. View

10.

Alam N, Shepherd F, Winton T, Graham B, Johnson D, Livingston R . Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005; 47(3):385-94. DOI: 10.1016/j.lungcan.2004.08.016. View

11.

Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K . Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996; 7(5):548-57. DOI: 10.1097/00001813-199607000-00010. View

12.

Hutchins L, Unger J, Crowley J, COLTMAN Jr C, Albain K . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27):2061-7. DOI: 10.1056/NEJM199912303412706. View

13.

Fujii S, Kitano S, Ikenaka K, Shirasaka T . Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gan. 1979; 70(2):209-14. View

14.

Strauss G, Herndon 2nd J, Maddaus M, Johnstone D, Johnson E, Harpole D . Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008; 26(31):5043-51. PMC: 2652093. DOI: 10.1200/JCO.2008.16.4855. View

15.

Scagliotti G, Fossati R, Torri V, Crino L, Giaccone G, Silvano G . Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003; 95(19):1453-61. DOI: 10.1093/jnci/djg059. View

16.

Cuffe S, Booth C, Peng Y, Darling G, Li G, Kong W . Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol. 2012; 30(15):1813-21. DOI: 10.1200/JCO.2011.39.3330. View

17.

Douillard J, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba J . Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7(9):719-27. DOI: 10.1016/S1470-2045(06)70804-X. View

18.

Wada H, Hitomi S, TERAMATSU T . Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996; 14(4):1048-54. DOI: 10.1200/JCO.1996.14.4.1048. View

19.

Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M . Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005; 23(22):4999-5006. DOI: 10.1200/JCO.2005.09.017. View

20.

Tsuchiya T, Nagayasu T, Yamasaki N, Matsumoto K, Miyazaki T, Tagawa T . A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates. Clin Lung Cancer. 2012; 13(6):464-9. DOI: 10.1016/j.cllc.2012.01.005. View